Nanotechnology approaches in the current therapy of skin cancer

Borgheti-Cardoso, Lívia Neves; Viegas, Juliana Santos Rosa; Silvestrini, Ana Vitória Pupo; Caron, Angelo Luis; Praça, Fabíola Silva Garcia; Kravicz, Marcelo; Bentley, Maria Vitória Lopes Badra

doi:10.1016/j.addr.2020.02.005

Cited by 84 publications

(45 citation statements)

References 350 publications

(504 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, nanotechnology-mediated drug delivery is a leading approach to achieve controlled drug release, co-delivery of primary and adjuvant therapeutics, protecting/minimizing the drug-associated adverse events, and improving the overall drug biopharmaceutical performance [ 9 , 10 ]. For the topical route of administration, the nanocarrier-mediated delivery has a role in reducing the skin irritation associated with the immediate release of some active pharmaceutical ingredients (APIs) by controlling the rate of release [ 11 , 12 ] and enhancing the drug’s skin permeation [ 13 ] which results in a more effective treatment outcome and less adverse effects.…”

Section: Introductionmentioning

confidence: 99%

Co-Delivery of Imiquimod and Curcumin by Nanoemugel for Improved Topical Delivery and Reduced Psoriasis-Like Skin Lesions

2020

View full text Add to dashboard Cite

The current investigation aimed to improve the topical efficacy of imiquimod in combination with curcumin using the nanoemulsion-based delivery system through a combinatorial approach. Co-delivery of curcumin acts as an adjuvant therapeutic and to minimize the adverse skin reactions that are frequently associated with the topical therapy of imiquimod for the treatment of cutaneous infections and basal cell carcinomas. The low-energy emulsification method was used for the nano-encapsulation of imiquimod and curcumin in the nanodroplet oil phase, which was stabilized using Tween 20 in an aqueous dispersion system. The weak base property of imiquimod helped to increase its solubility in oleic acid compared with ethyl oleate, which indicates that fatty acids should be preferred as the oil phase for the design of imiquimod-loaded topical nanoemulsion compared with fatty acid esters. The phase diagram method was used to optimize the percentage composition of the nanoemulsion formulation. The mean droplet size of the optimized nanoemulsion was 76.93 nm, with a polydispersity index (PdI) value of 0.121 and zeta potential value of −20.5 mV. The optimized imiquimod-loaded nanoemulsion was uniformly dispersed in carbopol 934 hydrogel to develop into a nanoemulgel delivery system. The imiquimod nanoemulgel exhibited significant improvement (p < 0.05) in skin permeability and deposition profile after topical application. The in vivo effectiveness of the combination of imiquimod and curcumin nanoemulgel was compared to the imiquimod nanoemulgel and imiquimod gel formulation through topical application for ten days in BALB/c mice. The combination of curcumin with imiquimod in the nanoemulgel system prevented the appearance of psoriasis-like symptoms compared with the imiquimod nanoemulgel and imiquimod gel formulation entirely. Further, the imiquimod nanoemulgel as a mono-preparation slowed and reduced the psoriasis-like skin reaction when compared with the conventional imiquimod gel, and that was contributed to by the control release property of the nano-encapsulation approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Co-Delivery of Imiquimod and Curcumin by Nanoemugel for Improved Topical Delivery and Reduced Psoriasis-Like Skin Lesions

2020

View full text Add to dashboard Cite

show abstract

“…In this respect, several nanoformulations can enhance the efficacy of drugs to treat cancer; thus, this approach will allow well-known drugs to be used to treat skin cancer. Although nanosystems for skin cancer are not commercially available, several formulations have been proposed as nanocarriers to effectively deliver known antineoplastic therapeutic agents for skin cancers ( 102 , 103 ).…”

Section: Discussionmentioning

confidence: 99%

Repurposing of Drug Candidates for Treatment of Skin Cancer

et al. 2021

View full text Add to dashboard Cite

Skin cancers are highly prevalent malignancies that affect millions of people worldwide. These include melanomas and nonmelanoma skin cancers. Melanomas are among the most dangerous cancers, while nonmelanoma skin cancers generally exhibit a more benign clinical pattern; however, they may sometimes be aggressive and metastatic. Melanomas typically appear in body regions exposed to the sun, although they may also appear in areas that do not usually get sun exposure. Thus, their development is multifactorial, comprising endogenous and exogenous risk factors. The management of skin cancer depends on the type; it is usually based on surgery, chemotherapy, immunotherapy, and targeted therapy. In this respect, oncological treatments have demonstrated some progress in the last years; however, current therapies still present various disadvantages such as little cell specificity, recurrent relapses, high toxicity, and increased costs. Furthermore, the pursuit of novel medications is expensive, and the authorization for their clinical utilization may take 10–15 years. Thus, repositioning of drugs previously approved and utilized for other diseases has emerged as an excellent alternative. In this mini-review, we aimed to provide an updated overview of drugs’ repurposing to treat skin cancer and discuss future perspectives.

show abstract

“…Recently, Kang et al 162 investigated the anti-fibrotic activity of siRNA against CTGF using mesoporous silica nanoparticles (MSNs). MSNs are attractive carriers due to their high surface area and large pore sizes 163,164 . Moreover, the ease of surface modification makes them a suitable option for siRNA loading 163 .…”

Section: Mesoporous Silica Nanoparticlesmentioning

confidence: 99%

Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

Sallam

Prakash

Kumbhojkar

et al. 2021

Bioengineering & Transla Med

View full text Add to dashboard Cite

A growing variety of biological macromolecules are in development for use as active ingredients in topical therapies and vaccines. Dermal delivery of biomacromolecules offers several advantages compared to other delivery methods, including improved targetability, reduced systemic toxicity and decreased degradation of drugs. However, this route of delivery is hampered by the barrier function of the skin. Recently, a large body of research has been directed towards improving the delivery of macromolecules to the skin, ranging from nucleic acids to antigens, using noninvasive means. In this review, we discuss the latest formulation-based efforts to deliver antigens and nucleic acids for vaccination and treatment of skin diseases. We provide a perspective of their advantages, limitations and potential for clinical translation. The delivery platforms discussed in this review may provide formulation scientists and clinicians with a better vision of the alternatives for dermal delivery of biomacromolecules, which may facilitate the development of new patientfriendly prophylactic and therapeutic medicines.

show abstract

Nanotechnology approaches in the current therapy of skin cancer

Cited by 84 publications

References 350 publications

Co-Delivery of Imiquimod and Curcumin by Nanoemugel for Improved Topical Delivery and Reduced Psoriasis-Like Skin Lesions

Co-Delivery of Imiquimod and Curcumin by Nanoemugel for Improved Topical Delivery and Reduced Psoriasis-Like Skin Lesions

Repurposing of Drug Candidates for Treatment of Skin Cancer

Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

Contact Info

Product

Resources

About